Grade 3/4 treatment-related adverse events, including thrombocytopenia (11.1%), diarrhea (2.8%), anemia (2.8%), increased alanine aminotransferase (2.8%), and increased aspartate aminotransferase (2.8%), occurred in 5 participants. The gene discussed is GPT; the disease is anemia.